J&J Product Targeting Histamine H3 Receptor Moves Into Clinic
Executive Summary
Johnson & Johnson is moving a drug candidate targeting the histamine H3 receptor into clinical development in half the time it has historically taken to advance a candidate, J&J Pharmaceuticals Group Worldwide Chairman William Weldon told an April 18 teleconference.
You may also be interested in...
J&J Procrit Will Rely On New Indications, DTC To Compete With Amgen NESP
Johnson & Johnson is focusing on consumer education and line extensions to position Procrit for impending competition from Amgen's NESP.
J&J Procrit Will Rely On New Indications, DTC To Compete With Amgen NESP
Johnson & Johnson is focusing on consumer education and line extensions to position Procrit for impending competition from Amgen's NESP.
Propulsid Limited Access Program Allows Off-Label Use To Continue
FDA and Johnson & Johnson are indicating that the new Propulsid limited access program will allow physicians to continue prescribing the drug for more serious conditions than nocturnal heartburn due to gastroesophageal reflux disease, the labeled indication.